All Press Releases
PILA PHARMA: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE – CEO & FOUNDER’S PARTICIPATION DISCLOSED
Malmö, 05 March 2026 PILA PHARMA AB (publ) (FN STO: PILA) ("PILA" or "the Company"), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, informs of the conversion of TO2 warrants to shares, and the disclosure of participation from management members. Malmö, 05 March 2026 The subscription period for exercise of the warrants of series TO2 took…
PILA PHARMA: MANAGEMENT TEAM COMMENTS ON OUTCOME OF TO2 WARRANTS
Malmö, 17 February 2026 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs based on TRPV1 inhibition, today announced the outcome of exercise in warrants of series TO2. The subscription period for exercise of the warrants of series TO2 took place during the period from and including 5 February 2026, up to and including…
PILA PHARMA ANNOUNCES THE OUTCOME IN THE EXERCISE OF WARRANTS OF SERIES TO2
Malmö, 17 February 2026 THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION…